Lamellar Biomedical’s LAMELLASOME™ Nucleic Acid Transfer technology delivers nucleic acids to a diverse range of cells, offering the opportunity to realise the potential of active-agent nucleic acids, including microRNAs, siRNAs, mRNAs and plasmids, and revolutionising the treatment of many diseases.
LAMELLASOME formulations are dispersions of lipid vesicles with compositions based on human lamellar bodies/exosomes. The LAMELLASOME formulations are purely synthetic. As such, they do not require harvesting or human extraction, and they can be manufactured using standard industry processes. They have been proven to be safe and exhibit remarkably low immunogenicity, and they can be optimised to deliver functional therapeutic payloads of specific nucleic acids to a range of cell types and diseases.